Designation
In Vitro
In Vivo
Phase 1
Phase 2
Phase 3
Pipeline
Obesity
MASLD
GRN-1
Colorectal
Adenocarcinoma
CA-1
GABRA1
GABA-A Variant
GABA-A Variant
GABRG2
Rett Syndrome
RTT1
Obesity/MASLD
One of the most promising therapeutics in our pipeline, GRN-1, has been observed to reduce adipose tissue buildup (body fat) in in vivo trials with MS-NASH mice afflicted with hepatic steatosis. Utilizing our mRNA-LNP technology, our patented GRN-1 therapeutic has the ability to reverse liver cirrhosis, as well as eliminate excess fat on the liver in vivo.
Our results indicate promising avenues for future research and clinical treatment in humans affected with Metabolic dysfunction-associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD). Other conditions where this therapeutic can be applied consist of alcoholic, metabolic, or lysosomal storage related diseases or any disease which causes excess adipose tissue buildup and inflammation.
The images and data detailed in the pitch deck link illustrate a comparison between mice dosed with our experimental, patented mRNA-SLN therapeutic, GRN-1, to mice dosed with empty solid lipid nanoparticles (SLNs). Comparison chart from GRN-1 writeup below.
GRN-1 Liver Images
Control Liver
GRN-1 Dosed Liver
Blood-Brain Barrier
Grann Pharmaceuticals Inc. has put forth continued research efforts into developing a lipid nanoparticle delivery system capable of crossing the Blood Brain Barrier (BBB). Current research indicates that any particle < 100 nm - 150 nm has the capability to cross the BBB (Nance et al., 2012).
Here at Grann Pharmaceuticals, we have tailored our lipid nanoparticles to an average size of 80 nm to successfully deliver mRNA and small molecules across the BBB. This has been observed in multiple animal trials spanning across several different species of mice.
Our goal at Grann Pharmaceuticals is to apply this lipid nanoparticle technology in therapeutics for CNS disorders and neurological diseases such as Obesity, Rett Syndrome, GABA-A Variants, Alzheimer’s and cancer.
